INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Kymriah GMP issues in NJ led to FDA letter for Novartis—Is gene therapy on its last legs?

Kymriah GMP issues in NJ led to FDA letter…

Hedley Rees
Dec 8, 2023
13

Share this post

INSIDE PHARMA
INSIDE PHARMA
Kymriah GMP issues in NJ led to FDA letter for Novartis—Is gene therapy on its last legs?
1

This thread is only visible to paid subscribers of INSIDE PHARMA

Subscribe to view →

Comments on this post are for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share